Related Experiment Video

Updated: Jun 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new

Kyle A Furge1, Jeffrey P MacKeigan, Bin T Teh

  • 1Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, MI, USA.

The Lancet. Oncology
|April 13, 2010
PubMed

Insights

Molecularly-targeted kinase inhibitors show promise for treating advanced renal-cell carcinoma (RCC). These therapies target key signaling pathways, offering improved progression delay compared to traditional treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal-cell carcinoma (RCC) is a diverse kidney tumor group with poor outcomes from traditional therapies.
  • Advanced RCC demonstrates limited response to chemotherapy and radiation, necessitating novel treatment strategies.
  • Molecularly-targeted inhibitors have emerged as effective treatments for advanced RCC.

Purpose of the Study:

  • To review the current use of molecularly-targeted kinase inhibitors in renal-cell carcinoma treatment.
  • To explore the genetic complexity of renal tumors and identify new therapeutic targets.
  • To highlight next-generation kinase inhibitors with potential for improved RCC treatment.

Main Methods:

  • Review of scientific literature on kinase inhibitors and renal-cell carcinoma.
  • Analysis of gene-expression profiling and molecular-genetic data in renal tumors.
  • Discussion of targeted therapies focusing on vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) pathways.

Main Results:

  • Molecularly-targeted kinase inhibitors, particularly those inhibiting VEGFR and mTOR pathways, are effective in delaying advanced RCC progression.
  • Genetic complexity of RCC suggests that targeting additional kinase pathways could further inhibit tumor growth.
  • Current targeted therapies offer improved outcomes over traditional treatments for advanced renal tumors.

Conclusions:

  • Molecularly-targeted kinase inhibitors represent a significant advancement in managing advanced renal-cell carcinoma.
  • Further research into novel kinase targets and inhibitors is crucial for enhancing RCC treatment efficacy.
  • The future of RCC treatment lies in personalized therapies that exploit the molecular intricacies of the disease.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...